SARS-CoV-2 Protein Nanoparticle Vaccines Formed In Situ From Lyophilized Lipids
Description
The receptor binding domain (RBD) of the SARS-CoV-2 Spike (S) glycoprotein is an appealing immunogen, but associated vaccine approaches must overcome the hapten-like nature of the compact protein and adapt to emerging variants with evolving RBD
